Buy Rating for COMPASS Pathways: Accelerated Clinical Development and Strategic Position in Mental Health Sector
I'm PortAI, I can summarize articles.
Maxim Group analyst Michael Okunewitch has maintained a Buy rating on COMPASS Pathways with a price target of $12.00, citing the company's accelerated clinical development in the mental health sector. Key factors include proactive studies on psilocybin therapy, regulatory insights, and institutional support for psychedelic therapies. Additionally, COMPASS's application for the Commissioner’s National Priority Voucher could expedite market entry. H.C. Wainwright also reiterated a Buy rating with a $40.00 target, reflecting confidence in the company's upcoming data releases and strong cash position.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments